申请人:Advinus Therapeutics Private Limited
公开号:US20150087643A1
公开(公告)日:2015-03-26
The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.
本发明揭示了式(I)的取代融合嘧啶化合物,它们的互变异构体、多晶形、立体异构体、溶剂化物、药学上可接受的盐或含有它们的制药组合物以及治疗通过腺苷受体(AR)活性介导的疾病和病症的方法;本发明中的化合物在治疗、预防或抑制疾病和疾病方面有用,这些疾病和疾病可能通过拮抗腺苷受体而容易改善,例如哮喘、慢性阻塞性肺疾病、血管生成、肺纤维化、肺气肿、过敏性疾病、炎症、再灌注损伤、心肌缺血、动脉粥样硬化、高血压、充血性心力衰竭、视网膜病变、糖尿病、肥胖、炎症性肠道疾病和/或自身免疫性疾病。